Marekani - Kiingereza - NLM (National Library of Medicine)

remedyrepack inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 20 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g. digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patien

Marekani - Kiingereza - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 20 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g. digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patien

Marekani - Kiingereza - NLM (National Library of Medicine)

virtus pharmaceuticals llc - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 3.3 g

Marekani - Kiingereza - NLM (National Library of Medicine)

upsher-smith laboratories, inc. - potassium bicarbonate (unii: hm5z15lebn) (potassium cation - unii:295o53k152) - potassium cation 978 mg - - for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop (e.g., digitalized patients or patients with significant cardiac arrhythmias). the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarra

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - potassium citrate; citric acid monohydrate - oral solution - 300mg/1ml ; 50mg/1ml

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - potassium citrate; citric acid monohydrate - oral solution - 300mg/1ml ; 50mg/1ml

Marekani - Kiingereza - NLM (National Library of Medicine)

remedyrepack inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 10 meq - potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)] . potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)] . potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)] . urocit ® -k is contraindicated: - in patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those sufferi

Marekani - Kiingereza - NLM (National Library of Medicine)

mckesson packaging services business unit of mckesson corporation - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with extended-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such pat

Marekani - Kiingereza - NLM (National Library of Medicine)

contract pharmacy services-pa - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 10 meq - because of reports of intestinal and gastric ulceration and bleeding with extended-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitais intoxication and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a

Marekani - Kiingereza - NLM (National Library of Medicine)

ethex - potassium chloride (unii: 660yq98i10) (potassium ion - unii:295o53k152) - capsule, extended release - 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrhe